By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Lonza Group AG

Lonza Group AG (LZAGY)

OTC Market Data in USD, Fundamentals in CHF
$70.87
+$0.49
+0.70%
Last Update: 3 Sept 2025, 19:58
$50.03B
Market Cap
0.00
P/E Ratio (TTM)
0.59%
Forward Dividend Yield
$55.57 - $73.29
52 Week Range

LZAGY Stock Price Chart

Explore Lonza Group AG interactive price chart. Choose custom timeframes to analyze LZAGY price movements and trends.

LZAGY Company Profile

Discover essential business fundamentals and corporate details for Lonza Group AG (LZAGY) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

20 Jan 2010

Employees

18.00K

CEO

Wolfgang Wienand

Description

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

LZAGY Financial Timeline

Browse a chronological timeline of Lonza Group AG corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 27 Jan 2026

Earnings released on 23 Jul 2025

EPS came in at $0.95 surpassing the estimated $0.87 by +8.86%, while revenue for the quarter reached $4.50B , beating expectations by +4.37%.

Earnings released on 14 May 2025

EPS came in at $4.74 surpassing the estimated $0.88 by +438.02%, while revenue for the quarter reached $3.87B , missing expectations by -0.42%.

Dividend declared on 29 Apr 2025

A dividend of $0.42 per share was announced, adjusted to $0.42. The dividend was paid on 30 May 2025.

Earnings released on 25 Jul 2024

EPS came in at $5.15 surpassing the estimated $4.90 by +5.10%, while revenue for the quarter reached $3.41B , beating expectations by +2.55%.

Dividend declared on 15 May 2024

A dividend of $0.44 per share was announced, adjusted to $0.44. The dividend was paid on 29 May 2024.

Earnings released on 29 Jan 2024

EPS came in at $3.92 falling short of the estimated $8.02 by -51.12%, while revenue for the quarter reached $4.25B , beating expectations by +8.92%.

Earnings released on 30 Jun 2023

EPS came in at $6.15 surpassing the estimated $0.76 by +711.35%, while revenue for the quarter reached $3.43B , missing expectations by -4.62%.

Dividend declared on 16 Mar 2023

A dividend of $0.38 per share was announced, adjusted to $0.38. The dividend was paid on 26 May 2023.

Earnings released on 25 Jan 2023

EPS came in at $10.52 surpassing the estimated $0.77 by +1.26K%, while revenue for the quarter reached $3.50B , beating expectations by +3.35%.

Earnings released on 22 Jul 2022

EPS came in at $6.90 surpassing the estimated $0.74 by +827.42%, while revenue for the quarter reached $3.11B , beating expectations by +3.26%.

Dividend declared on 11 May 2022

A dividend of $0.31 per share was announced, adjusted to $0.31. The dividend was paid on 26 May 2022.

Earnings released on 6 May 2022

EPS came in at $38.54 surpassing the estimated $0.87 by +4.35K%, while revenue for the quarter reached $3.14B , beating expectations by +9.26%.

Earnings released on 21 Oct 2021

EPS came in at $4.63 surpassing the estimated $0.53 by +770.30%, while revenue for the quarter reached $2.75B , beating expectations by +2.52%.

Earnings released on 7 May 2021

EPS came in at $5.93 surpassing the estimated $0.72 by +719.06%, while revenue for the quarter reached $1.62B , missing expectations by -51.80%.

Dividend declared on 21 Apr 2021

A dividend of $0.33 per share was announced, adjusted to $0.33. The dividend was paid on 27 May 2021.

Earnings released on 10 Nov 2020

EPS came in at $6.76 surpassing the estimated $0.74 by +817.23%, while revenue for the quarter reached $3.25B , missing expectations by -1.49%.

LZAGY Stock Performance

Access detailed LZAGY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run